For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Ecolab Inc. (ECL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -8 (−100…+100 Quality+Value blend) · Quality 73 · Value -75 · Sentiment -23 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Ecolab Inc.
ECL NYSEEcolab Inc. is a global specialty chemicals and services company focused on water, hygiene, and infection prevention solutions for institutional, industrial, and healthcare customers. The company provides cleaning and sanitation products, water treatment chemicals, and on-site service programs that help businesses maintain clean and safe operations while managing resource use and regulatory requirements. Its key business segments include Global Industrial, Global Institutional and Specialty, Global Healthcare and Life Sciences, and Global Pest Elimination, serving sectors such as food and beverage processing, hospitality, manufacturing, healthcare, and life sciences. Ecolab’s offerings range from dishwashing and laundry systems to customized water management solutions and pest control services, often delivered with technical support and monitoring. Headquartered in St. Paul, Minnesota and founded in 1923, Ecolab plays a significant role in enabling operational efficiency, public health standards, and environmental compliance for commercial and industrial facilities worldwide.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 7.28
Total Equity: $9.80B
Shares: 285,200,000
Total Debt: $870.40M
Cash: $646.20M
EBITDA: $3.71B
Total Debt: $870.40M
Cash: $646.20M
Revenue: $16.08B
Revenue: $16.08B
Revenue: $16.08B
Total Equity: $9.80B
Tax Rate: 17.8%
Equity: $9.80B
Total Debt: $870.40M
Cash: $646.20M
Current Liabilities: $5.53B
Long-Term Debt: $0.00
Total Debt: $870.40M
Total Equity: $9.80B
Shares: 285,200,000
Shares: 285,200,000
CapEx: -$1.05B
Shares: 285,200,000
Stock Price: $285.36
Net Income: $2.08B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 11, 2026 10:43am (12d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $12.7B | $14.2B | $15.3B | $15.7B | $16.1B |
| Cost of Revenue | $7.6B | $8.8B | $9.2B | $8.9B | $8.9B |
| Gross Profit | $5.1B | $5.4B | $6.2B | $6.8B | $7.2B |
| Operating Expenses | $3.5B | $3.8B | $4.2B | $4.0B | $4.4B |
| Operating Income | $1.6B | $1.6B | $2.0B | $2.8B | $2.7B |
| Net Income | $1.1B | $1.1B | $1.4B | $2.1B | $2.1B |
| EBITDA | $2.4B | $2.5B | $2.9B | $3.7B | $3.7B |
| EPS | $3.95 | $3.83 | $4.82 | $7.43 | $7.33 |
| EPS (Diluted) | $3.91 | $3.81 | $4.79 | $7.37 | $7.28 |
Balance Sheet (Annual)
Last updated: Aug 11, 2026 10:20am (12d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $359.9M | $598.6M | $919.5M | $1.3B | $646.2M |
| Total Current Assets | $4.7B | $5.5B | $5.6B | $6.0B | $6.0B |
| Total Assets | $21.2B | $21.5B | $21.8B | $22.4B | $24.7B |
| Current Liabilities | $3.6B | $4.2B | $4.3B | $4.8B | $5.5B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $14.0B | $14.2B | $13.8B | $13.6B | $14.9B |
| Total Equity | $7.3B | $7.3B | $8.1B | $8.8B | $9.8B |
| Retained Earnings | $8.8B | $9.3B | $10.1B | $11.5B | $12.8B |
Cash Flow (Annual)
Last updated: Aug 11, 2026 10:43am (12d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.1B | $1.8B | $2.4B | $2.8B | $3.0B |
| Capital Expenditure | -$643.0M | -$712.8M | -$774.8M | -$994.5M | -$1.0B |
| Free Cash Flow | $1.4B | $1.1B | $1.6B | $1.8B | $1.9B |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | $1.8B | $494.0M | -$500.0M | -$630.4M | $371.4M |
| Dividends Paid | -$566.4M | -$602.8M | -$617.3M | -$664.3M | -$753.6M |
| Stock Buybacks | -$106.6M | -$518.2M | -$13.7M | -$986.5M | -$783.8M |
| Net Change in Cash | -$900.3M | $238.7M | $320.9M | — | — |
Growth Trends (YoY %)
Last updated: Aug 11, 2026 10:43am (12d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +11.4% | +8.0% | +2.7% | +2.2% |
| Gross Profit Growth | +4.7% | +15.1% | +11.0% | +4.5% |
| Operating Income Growth | -2.3% | +27.5% | +40.7% | -2.3% |
| Net Income Growth | -3.4% | +25.7% | +53.9% | -1.7% |
| EBITDA Growth | +2.4% | +16.6% | +28.2% | -0.6% |
Dividend History (Last 20)
Last updated: Aug 11, 2026 10:21am (12d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-16 | $0.73 | — | — | — |
| 2026-03-17 | $0.73 | — | — | — |
| 2025-12-16 | $0.73 | — | — | — |
| 2025-09-16 | $0.65 | — | — | — |
| 2025-06-17 | $0.65 | — | — | — |
| 2025-03-18 | $0.65 | — | — | — |
| 2024-12-17 | $0.65 | — | — | — |
| 2024-09-17 | $0.57 | — | — | — |
| 2024-06-18 | $0.57 | — | — | — |
| 2024-03-18 | $0.57 | — | — | — |
| 2023-12-18 | $0.57 | — | — | — |
| 2023-09-18 | $0.53 | — | — | — |
| 2023-06-16 | $0.53 | — | — | — |
| 2023-03-20 | $0.53 | — | — | — |
| 2022-12-19 | $0.53 | — | — | — |
| 2022-09-19 | $0.51 | — | — | — |
| 2022-06-17 | $0.51 | — | — | — |
| 2022-03-14 | $0.51 | — | — | — |
| 2021-12-13 | $0.51 | — | — | — |
| 2021-09-13 | $0.48 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-11Roughly half of Ecolab's cost-to-serve is a ~25k-person field sales-and-service organization; remote sensing plus AI-directed routing, dosing control and predictive maintenance lets fewer technicians cover more sites, and Ecolab has historically held value-based pricing while delivery cost falls — the exact pattern behind the 2021→2025 op-margin move from 12.6% to 17%.
The core product is still consumable chemistry: if AI optimization genuinely cuts customer water, energy and detergent consumption, Ecolab risks making its own volume unit smaller unless outcome-based pricing captures the savings — the 'more useful, less revenue' trap.
Whether digital/outcome contracts price on customer savings rather than gallons and pounds. Watch disclosed organic growth split between price and volume, and management commentary on digitally-enabled recurring revenue per site.
On-premise dispensing equipment installed inside customer plants, thousands of chemical registrations and food-safety/EPA approvals, audited compliance records regulators and insurers accept, and a field force with physical access to restricted industrial sites.
AI Lens thesis
Ecolab is hired to keep water systems, food plants and hospitals safe and compliant — a need that cheap intelligence intensifies rather than removes, since somebody must still be accountable for a Legionella outbreak or a failed sanitation audit. AI cannot dose a cooling tower or clean a fryer; it can only re-time and re-target those actions. So the transmission runs two ways: inward, as a labor-productivity and route-density lever on Ecolab's largest cost pool and as a reason to keep raising the installed-sensor base's switching cost; and outward, as a threat to consumable volume if efficiency gains are passed through untaxed, plus a modest arming of asset-light rivals (Solenis, ChemTreat) who can bolt AI monitoring onto competing chemistry without Ecolab's service overhead. A distinct, underrated positive: AI datacenter buildouts are water- and cooling-intensive, and Ecolab sells directly into that thermal-management and water-reuse problem.
What the market may be underestimating
Upside AI infrastructure is a customer, not just a tool: hyperscale cooling loops, water reuse and heat-transfer chemistry are recurring-service problems Ecolab already sells, giving it a rare Basic Materials line into datacenter capex without owning silicon risk.
Downside Remote monitoring can decouple the chemistry from the technician — once telemetry is standardized, procurement can competitively bid the molecule and keep the dashboard, eroding the bundled service premium that justifies Ecolab's pricing.
Outcome range spread 36
Claude Reading
Looking at the raw quarterly cadence first: revenue went from $3.99B (2Q24) to $4.07B (1Q26) — that's roughly 2% total growth over seven quarters, essentially flat. The 23% earnings CAGR the momentum module cites is arithmetic noise from a depressed 2021-2022 base (NI $1.09B → $2.08B), not a live growth engine. Sequential Q1'26 revenue actually declined from $4.20B to $4.07B, and net income dropped to $432.6M (10.6% margin) from $563.9M — the margin story is wobbling, not compounding. The 2024 Q3 print of $736.5M NI at 18.4% margin looks like an outlier (tax or one-time item) that flatters the trailing base. Strip it out and net income is meandering in the $400-580M quarterly band with no clear upward slope. Trailing four quarters of NI is roughly $2.10B — flat to down versus 2024's $2.11B.
On valuation, I largely agree with the synthesis but not with its precision. At $285 and ~$79.7B market cap on $2.1B of earnings, that's 38x trailing, ~5x sales, and ~21.8x EV/EBITDA for a business growing revenue 2.2% YoY with earnings going backwards. ROIC of 22% and ROE of 21% are genuinely excellent and justify a premium — but not this premium. A quality-compounder peer set (SHW, ROP, IEX) trades 25-30x for similar quality, and ECL's growth is at the low end of that cohort. The synthesis fair value of $127-$143 feels punitive; I'd anchor fair value closer to $180-$210 (roughly 28-32x on $2.1B NI, adjusting for FCF quality and balance sheet strength — net debt is trivial at $224M against $2.95B OCF). Either way, at $285 you're paying ~35-45% above a defensible fair value.
Where a contrarian pushes back: (1) ECL's pricing power in water/hygiene is real, and the Life Sciences and Ecolab Digital businesses could reaccelerate the top line above 2% — management has guided to mid-to-high-single-digit organic. (2) Gross margin has expanded from 40.2% (2021) to 44.5% (2025), which is durable if raw material tailwinds hold and mix shift continues. (3) FCF of $1.90B is high quality — 90%+ conversion of net income — and the buyback/dividend combo is a floor. (4) The insider activity flag as "Net Insider Buying" is misleading: those are all A-Award grants (RSU vests), not open-market purchases. That's not a bullish signal, and the models leaning on it are wrong. I'd downgrade that secondary signal to neutral/negative given no cash-out-of-pocket buying at $285.
The models are internally inconsistent in a revealing way: pre-flight calls it "traditional" while narrative tags it "platform-monopoly" — both can't be right, and the market is clearly paying the platform-monopoly multiple for a traditional specialty chemicals business. I side with pre-flight: this is a very good traditional industrial with a services layer, not a platform. That mismatch is exactly the setup for multiple compression. The narrative-vs-fundamentals split ($143 DCF vs $285 price) is the cleanest tell in the file — you're paying ~$140/share for a story about perpetual margin expansion and ESG-driven pricing power, on top of ~$145 of demonstrable cash flow value. Data thinness: the Q1'26 print is a single quarter and could be seasonal; I want two more quarters before calling the margin rollover a trend. Also the annual balance sheet is 12/2025 while quarterly is 3/2026 — a 6-month gap during which debt could have moved.
I agree with the synthesis direction (overvalued) but dissent on magnitude — $143 is too low, $285 is too high, and fair value is $180-$210. This isn't a short (quality is real, balance sheet is fortress, FCF is strong, and narrative stocks can stay expensive for years), but it's not a buy at these levels. The asymmetric setup is bad: limited upside from further multiple expansion (already at 39x), meaningful downside if 2026 growth doesn't reaccelerate to the 5-7% organic the multiple implies. Q1'26 margin compression to 10.6% is the first crack — watch Q2'26 closely. If margin holds above 13%, the story survives; if it prints another sub-12% quarter, expect a re-rating toward $200.
GPT Reading
Ecolab’s numbers describe a genuinely excellent business that the market is treating like an even better one. The core operating picture is sturdy: revenue has climbed from $12.73B in 2021 to $16.08B in 2025, a roughly 6% annualized pace over that full period, and margins have clearly recovered from the 2022–2023 squeeze. Gross margin is now 44.5%, operating margin 17.0%, net margin 12.9%, versus 2022 levels of 37.8%, 11.0%, and 7.7%. Return metrics are strong enough to justify a premium: ROE 21.2%, ROIC 22.4%, and free cash flow of $1.90B on $2.95B of operating cash flow. The balance sheet is also a plus, with just $870M of debt against $646M of cash and $9.8B of equity. This is not a low-quality chemicals name dressed up as defensive; it is a high-quality, mission-critical service-and-chemicals franchise with real pricing power and attractive capital efficiency.
But the recent trend is less exciting than the stock price implies. 2025 revenue was only $16.08B versus $15.74B in 2024, up 2.2%, and operating income actually slipped from $2.80B to $2.74B while net income edged down from $2.11B to $2.08B. The quarterly sequence reinforces that this is now a steady grinder, not a fast compounder: Q1 2026 revenue was $4.07B, up about 10% from $3.70B a year earlier, but net income was only $432.6M versus $402.5M, and margin was 10.6% versus 10.9%. More importantly, the last three 2025 quarters were already running at $4.03B, $4.17B, and $4.20B of revenue, so the top line is hovering around a $16B–$16.5B annual run rate rather than inflecting sharply upward. If I put that together with a 39.2x P/E, 5.1x sales, and 21.8x EV/EBITDA, I get a stock priced for an extended runway of high-single-digit growth and further margin expansion that the raw results do not currently show.
The biggest mismatch is between quality and growth. Ecolab deserves a premium because its end markets are sticky, its service model is embedded, and cash generation is reliable. But a premium is not the same thing as an unlimited multiple. At nearly $80B of market cap on $2.08B of net income and $1.90B of free cash flow, investors are accepting earnings and FCF yields in the low-2% range for a business whose latest annual sales growth was 2.2% and whose recent earnings growth was negative. Even if you normalize away some quarter-to-quarter noise, this looks like a business that has already harvested much of its post-2022 margin recovery. From here, multiple risk dominates business risk: the company can execute well and the stock can still disappoint if it merely grows as a mature industrial-services franchise. I don’t buy the extreme valuation output of roughly $143 fair value as a precise target, because it likely under-credits durability and returns on capital, but I do think the stock is materially over-earning its multiple. A fairer range to me is closer to the low-$200s, where quality is still paid for, just not as if growth reaccelerates structurally.
The strongest counterargument is straightforward: this company has repeatedly shown that modest top-line growth can translate into disproportionately strong earnings power over time. Revenue rose only from $15.32B in 2023 to $16.08B in 2025, yet net income jumped from $1.37B to $2.08B, and gross profit expanded from $6.17B to $7.15B. That says mix, pricing, and productivity matter more here than raw volume growth, and it supports paying above-market multiples for a compounder with quasi-recurring revenue characteristics. A bull would also point to the very low leverage, the 1% dividend with only a 36% payout ratio, and the resilience of cash generation as signs that Ecolab can keep compounding through bolt-ons, buybacks, and steady margin gains. I weigh that differently because 2025 already showed the limits of the recovery trade: operating income and net income stopped rising despite another year of revenue growth. Once the margin snapback matures, a 39x earnings multiple needs more than “good and dependable.”
What would change my mind is not another quarter of 2%–3% growth with stable margins; the bar is higher at this valuation. I would turn more constructive if Ecolab can show two things simultaneously over the next few quarters: revenue growth sustaining above 6% and operating margin moving back above 18% without one-off help, which would imply annualized operating income power comfortably above $3.0B rather than the current ~$2.7B–$2.8B zone. If Q1 2026 turns out to be a temporary margin dip and the company starts printing quarterly net income consistently above $575M on revenues above $4.2B, then the premium multiple has real support. Absent that, I think investors are paying peak-quality multiples for a business whose current numbers say “excellent mature earner,” not “justify $285.”
Grok Reading
Ecolab’s numbers describe a high-quality franchise whose growth engine has already downshifted while the multiple has not. Annual revenue crawled from $15.74B in 2024 to $16.08B in 2025 (+2.2%), consistent with the 2.5% revenue CAGR, while operating income actually slipped from $2.80B to $2.74B and net income edged down to $2.08B from $2.11B. The 23% earnings CAGR is almost entirely the 2022–2024 margin-recovery story; once that reset finished, the incremental picture is low-single-digit top-line and flat-to-down earnings. Free cash flow of $1.90B on a $79.7B equity value produces a ~2.4% FCF yield—thin compensation for a mature specialty-chemicals name growing revenue at 2%. At 39.2× trailing earnings, 21.8× EV/EBITDA and 5.1× sales, the market is still capitalizing the post-recovery peak rather than the run-rate. The fortress balance sheet (net debt essentially zero, D/E 0.09, ROIC 22.4%) and sticky 44.5% gross margins justify a quality premium, not a near-doubling of any reasonable DCF anchor near $140–150.
Quarterly data sharpens the same point. The standout 18.4% net margin in Q3 2024 looks like a one-time gift; subsequent quarters settled into a 10.6–14% band, and the most recent print (Q1 2026) delivered $4.07B revenue and a 10.6% margin—respectable year-over-year dollar growth off an easy compare, but nothing that re-rates a 39× multiple. Cash conversion remains excellent (OCF $2.95B, FCF $1.90B after $1.05B capex), which is why the business deserves to trade above industrial averages; it does not explain paying roughly twice the cash-flow value the models surface. The “Net Insider Buying” secondary signal is also noise: the last ten filings are all A-Awards, not open-market purchases, so there is no incremental insider conviction to lean on.
The strongest counter-argument is straightforward and deserves weight. Ecolab’s ROIC of 22%, ROE of 21%, and near-zero leverage are rare in Basic Materials; the customer lock-in around water treatment, hygiene, and infection prevention really does create semi-utility economics and pricing power through cycles. A bull can point to the Q1 2026 revenue step-up versus the year-ago $3.70B, the still-elevated operating margin of 17%, and the secular ESG/water scarcity narrative that has historically supported 30–40× multiples for the name. If organic growth re-accelerates into the mid-single digits and mix continues to shift toward higher-margin healthcare and life-sciences services, the current price could simply be the market correctly refusing to fade a compounding machine. I weigh that case less heavily because the trailing five-year revenue path already embeds the recovery and the M&A/mix story, yet growth has compressed to ~2% while operating profit stalled; paying 39× for that outcome leaves almost no margin of safety if the next downturn or competitive pressure compresses the multiple even halfway toward sector norms.
I would reverse to neutral or constructive on a sustained print of mid-single-digit organic revenue growth with operating margins holding or expanding above 18%, or on a price decline into the $180–200 zone that restores a mid-20s earnings multiple and a 3.5%+ FCF yield. Until one of those arrives, the stock is a great business at a price that already discounts perfection.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has grown steadily from 12.73B in 2021 to 16.08B in 2025 (roughly 6% CAGR), but the more telling story is the margin expansion: gross margin lifted from 40.2% to 44.5% and operating margin from 12.6% to 17.0%, with net income nearly doubling from 1.13B to 2.08B. FCF has scaled in step, 1.42B to 1.90B, and OCF/NI of 1.6x with accruals at -3.8% of assets signals earnings that are backed by cash, not accruals. Beneish M of -2.51 and Altman Z of 4.98 corroborate clean books. Capital discipline is intact: diluted share count is actually down slightly (289.1M to 285.2M), SBC is a modest 0.9% of revenue, and buybacks run 4.4x SBC, so per-share value is being protected. Insider tape shows a small open-market purchase by Clark (263.8K) with the rest being routine director awards - not a strong signal either way. The one blemish is the balance sheet: 646M liquid cash against short-term debt of 870M and net debt of ~224M means liquidity is a constraint rather than a cushion, though 1.9B annual FCF trivially services it. This is a well-run mature earner executing operating leverage cleanly.
Verify before trusting this (5)
- Debt maturity schedule and refinancing plans for the 870M short-term debt
- Segment-level margin drivers behind the 2023-25 gross-margin expansion (mix, pricing, or input-cost tailwind)
- Customer concentration and contract structure across Industrial, Institutional, and Healthcare segments
- Sustainability of the OpM step-up to 17%+ vs. reversion risk if input costs re-inflate
- Any pending acquisitions or divestitures affecting the capital structure
The e2e composite pegs deserved value at $127.56 with a signal-adjusted $143.45, implying roughly -50% downside. The DCF ($91.71) and EPV floor ($76.86) both scream expensive, while the anchored-PE method at $249.95 is the only input in the same zip code as the $285.65 price - and even that sits ~14% below spot. Averaging skeptically around $150-160 (giving quality its due bump above pure DCF but not letting the PE anchor run the show) still leaves the stock ~45% above deserved value.
Verify before trusting this (4)
- Organic growth trajectory vs the 8-10% embedded in bull thesis - segment-level pricing vs volume
- Sustainability of margin expansion - is it operating leverage or one-time pricing catch-up post-inflation
- Capital returns pace (buyback + dividend) and whether FCF conversion continues to support the multiple
- Any large M&A or divestiture that would reset the earnings base and multiple
Ecolab sits under a mixed but net-neutral sentiment press. The platform-monopoly narrative (strong intensity, moderate durability) still frames ECL as a semi-utility ESG compounder, which is exactly the kind of story that wears well in a mildly risk-on tape (score +47, VIX 15.5, S&P near highs). With a beta of 0.89 the market tape barely amplifies moves either way, so macro is a soft, not decisive, input. Momentum is quietly positive and the low-cult, low-drama shareholder base means no forced narrative unwind. That is the tailwind side. The headwind side is getting louder. A fresh, explicit 'overvalued after 60% three-year run' article is exactly the kind of framing that starts to corrode a premium-multiple defensive name, especially with the 10y at 4.65% and market PE at 26 - rate-sensitive quasi-bond-proxies like ECL are precisely where DCF-vs-price gap articles bite. There is no visible analyst upgrade cycle or catalyst pulling the story forward, and the narrative is 'moderate' durability, not fortress. Net: the story is not breaking, but the marginal sentiment flow has turned mildly skeptical against a stretched multiple. Pressure is roughly balanced with a slight skew to headwind.
Verify before trusting this (4)
- Whether sell-side target revisions start trimming after the overvaluation piece gains traction
- Any rotation out of defensive quality into cyclicals or small caps that would leave ECL orphaned
- A move in the 10y toward 5% which would sharpen the duration headwind on premium defensives
- Fresh ESG/water regulatory catalyst that could re-energize the platform-monopoly story
Ecolab is hired to keep water systems, food plants and hospitals safe and compliant — a need that cheap intelligence intensifies rather than removes, since somebody must still be accountable for a Legionella outbreak or a failed sanitation audit. AI cannot dose a cooling tower or clean a fryer; it can only re-time and re-target those actions. So the transmission runs two ways: inward, as a labor-productivity and route-density lever on Ecolab's largest cost pool and as a reason to keep raising the installed-sensor base's switching cost; and outward, as a threat to consumable volume if efficiency gains are passed through untaxed, plus a modest arming of asset-light rivals (Solenis, ChemTreat) who can bolt AI monitoring onto competing chemistry without Ecolab's service overhead. A distinct, underrated positive: AI datacenter buildouts are water- and cooling-intensive, and Ecolab sells directly into that thermal-management and water-reuse problem.
None surfaced.
Verify before trusting this (8)
- Food-safety and water regulation tightening
- Hospital infection-prevention spend trends
- Industrial capacity utilization at customers
- Service visits per site trend
- Share of sites on remote monitoring
- Field headcount vs revenue growth
- Volume vs price split each quarter
- Outcome/subscription contract disclosure
This lens hasn't been run for this ticker yet.
When we made this prediction on Jul 14, 2026, ECL was $271.85. We expect it to be $240.91 by Jan 2027, and we consider it great value under $150.00. This is an early model (v0.3.0) — the direction is more reliable than the exact price. Made Jul 14, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.